ESN Cleer is developing novel drugs for orphan Cardiomyopathies where no guideline recommended treatments exist.
ESN Cleer has raised $1.3M in total funding. The most recent round was Grant. The last funding was announced in October 2022.
ESN Cleer's investors include WS Investments, Business.gov.au.
ESN Cleer is headquartered in Melbourne, Australia.
ESN Cleer is developing novel drugs for orphan Cardiomyopathies where no guideline recommended treatments exist.
ESN Cleer is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ESN Cleer — Funding & Investors." VCBacked, October 2, 2022, https://www.vcbacked.co/company/esn-cleer. Accessed August 14, 2026.
VCBacked. (2022). ESN Cleer — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/esn-cleer
{{cite web |title=ESN Cleer — Funding & Investors |url=https://www.vcbacked.co/company/esn-cleer |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated